Stock EX1 EXOPHARM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Exopharm Limited

Equities

EX1

AU0000030975

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 08:10:45 2023-10-01 pm EDT 		5-day change 1st Jan Change
0.0275 AUD +10.00% Intraday chart for Exopharm Limited -.--% -.--%
Feb. 26 Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
2023 Exopharm to Cut CEO Role Amid Cost Reductions MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023
Capitalization 1 33 23.87 87.97 20.44 3.515
Enterprise Value (EV) 1 28.59 23.04 76.61 19.33 3.406
P/E ratio -10.2 x -4.45 x -8.64 x -2.03 x -0.22 x
Yield - - - - -
Capitalization / Revenue - 8.95 x 21 x 4.86 x 1.04 x
EV / Revenue - 8.64 x 18.3 x 4.6 x 1 x
EV / EBITDA -12.7 x -4.5 x -9.67 x -2.16 x -0.6 x
EV / FCF -12,537,266 x -4,259,572 x -11,316,512 x -3,224,475 x -1,562,071 x
FCF Yield -0% -0% -0% -0% -0%
Price to Book 6.45 x 4.76 x 4.66 x 2.32 x 0.85 x
Nbr of stocks (in thousands) 32,200 38,189 62,839 62,885 175,769
Reference price 2 1.025 0.6250 1.400 0.3250 0.0200
Announcement Date 8/30/19 8/26/20 8/29/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.0439 - 2.665 4.192 4.206 3.393
EBITDA 1 -0.1741 -2.252 -5.125 -7.92 -8.955 -5.65
EBIT 1 -0.1747 -2.312 -5.339 -8.475 -10.01 -6.817
Operating Margin -397.7% - -200.32% -202.18% -237.87% -200.9%
Earnings before Tax (EBT) 1 -0.1746 -2.283 -5.279 -8.468 -10.08 -7.13
Net income 1 -0.1746 -2.283 -5.279 -8.468 -10.08 -7.13
Net margin -397.54% - -198.04% -202.02% -239.73% -210.14%
EPS 2 -0.0123 -0.1006 -0.1404 -0.1621 -0.1604 -0.0905
Free Cash Flow - -2.28 -5.409 -6.77 -5.996 -2.18
FCF margin - - -202.91% -161.5% -142.54% -64.26%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/6/18 8/30/19 8/26/20 8/29/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 0.05 4.42 0.83 11.4 1.1 0.11
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -2.28 -5.41 -6.77 -6 -2.18
ROE (net income / shareholders' equity) 4,350% -89.3% -104% -70.9% -72.9% -110%
ROA (Net income/ Total Assets) - -50.6% -55.9% -37.8% -35.7% -43.7%
Assets 1 - 4.51 9.446 22.38 28.28 16.31
Book Value Per Share 2 -0 0.1600 0.1300 0.3000 0.1400 0.0200
Cash Flow per Share 2 0 0.1400 0.0500 0.2000 0.0800 0.0100
Capex 1 0.02 0.53 0.63 1.63 1.13 0.28
Capex / Sales 47.81% - 23.7% 38.77% 26.75% 8.39%
Announcement Date 9/6/18 8/30/19 8/26/20 8/29/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EXOPHARM LIMITED Stock Exopharm Limited
-.--% 3.15M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EX1 Stock
  4. Financials Exopharm Limited